Scholarlink

<p>The advent of comprehensive genomic profiling has revolutionized not only the identification of the tissue of origin in cancer of unknown primary (CUP) but also enabled the detection of potentially actionable molecular alterations. Recent evidence demonstrates that molecularly targeted therapies improve outcomes in patients with unfavorable CUP harboring such alterations. This review summarizes current methods for determining the tissue of origin and discusses recent clinical trials evaluating molecularly guided therapies in unfavorable CUP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bridging the gap: targeted treatment strategies for cancer of unknown primary

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Leo Edlinger,
  • Valentina Egger,
  • Jakob Michael Riedl

摘要

The advent of comprehensive genomic profiling has revolutionized not only the identification of the tissue of origin in cancer of unknown primary (CUP) but also enabled the detection of potentially actionable molecular alterations. Recent evidence demonstrates that molecularly targeted therapies improve outcomes in patients with unfavorable CUP harboring such alterations. This review summarizes current methods for determining the tissue of origin and discusses recent clinical trials evaluating molecularly guided therapies in unfavorable CUP.